diagnost tool
price close busi august
market leader non-invas blood-
base prenat test enter larg liquid
biopsi cancer organ transplant test market
signatera draft lcd come earlier expect
continu execut cancer pt
roll year continu rate favorit
among top pick today palmetto moldx issu draft local coverag
determin final would provid medicar coverag signatera colon
cancer patient estim larger prospera kidney test
time lcd came earlier expect surpris see
execut initi oncolog believ lead step-funct
compani multipl trade rev discount
coverag univers continu view under-valued cancer compani
trade multipl nipt compani reiter buy rais pt
use rais multipl rev
earn posit lcd signatera patient today announc
determin lcd use ntra signatera molecular residu diseas mrd test
patient certain type colon cancer draft lcd propos medicar
coverag patient stratif surgeri decis regard
need chemo incorpor presenc absenc residu diseas
determin signatera cancer recurr detect patient previou
cancer diagnosi on-going clinic evid diseas test frequenc
line current nccn guidelin surveil use carcinoembryon antigen
test weve includ coverag indic limit page
time lcd come earlier expect spoke today said
time lcd came ahead intern expect ye
expect draft lcd turn final within month follow comment period
held expect lcd impact
guid think earli determin impact intern project
test frequenc expect rate doesnt know medicar rate
signatera believ may crosswalk cdna allosur and/
adpt clonoseq assay lack clear visibl see path signatera
reimburs per test rang indic physician
order signatera patient stratif post surgeri may order medicar
cover test within time frame physician order signatera
cancer recurr monitor may order medicar cover signatera assay per
year possibl increas frequenc monthli order well-reimburs
repeat test high gross margin well receiv investor view
signatera commerci strategi previous plan charg somewher
near test cogs/test signatera self-pay basi
small direct oncolog sale forc gener evid reimburs
given time today announc believ like look
expedit signatera commerci launch patient partnership and/or
distribut agreement recal februari announc agreement
subsidiari one lambda co-distribut kidney transplant reject test
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
model/ntra guid hold signatera revenu estim steadi
look addit visibl pace signatera
volumes/revenu call call rais high end
revenue guid
rais pt rais pt use multipl
revenu estim discount back two year discount rate
dilut share outstand formerli pt use multipl
revenu estim discount back two year discount rate
dilut share outstand
acog remain activ dialogu folk highest level acog
expect posit new bulletin average-risk nipt unfortun know
time result trim expect call
benefit acog offset view higher-than-expect revenu
partnership includ bgi believ stock price
posit new bulletin acog average-risk women remain major
catalyst believ impact volum revenu gross margin
meaning way time
major partnership deal come remind investor manag
indic call expect announc major partnership deal later
year think possibl announc deal thermo fisher allow
test content run ion torrent also think like could announc
larg partnership deal major pharmaceut compani believ either one
well receiv particularli meaning up-front payment
partner sourc non-dilut financ strengthen balanc sheet stood
million end
transplant expect launch prospera kidney test expect
draft lcd turn final come month announc launch
proactiv trial patient registri studi kidney largest kind
also launch second prospect multi-cent trial site may quell
stakehold concern tri cut corner
cancer data mount point see step-funct increas
stock multipl remind investor sit rich bodi data
highlight strong util monitor assay includ colorect cancer
sensit specif stage patient publish jama oncolog breast
cancer sensit specif publish clinic cancer research
bladder cancer sensit specif publish journal clinic
oncolog lung cancer sensit specif assert
customized-to-the-pati liquid biopsi track addit mutat
panel thu may detect relaps anoth panel might miss indic
signatera test detect circul tumor dna ctdna variant allel frequenc
vaf cell-fre dna provid deep depth coverag
buy unchang target price august
diagnost tool
coverag indic limit and/or medic necess taken directli
medicar contractor provid limit coverag signatera molecular
residu diseas assess call signatera inc san
differ kind test cover
diagnost laboratori test patient ajcc stage ii colon
cancer patient stage iia rectal cancer
diagnost laboratori test patient ajcc stage ii
colorect cancer patient presum cancer
time risk recurr ajcc stage ii colorect
singl test use test situat consist perform genet sequenc
solid tumor tissu sampl identifi singl nucleotid variant serv
clonal represent patient cancer follow seri assay
run blood detect presenc clonal sequenc seri assay
singl test use test situat consist assay detect
presenc clonal dna patient blood assay singl test
test describ diagnost laboratori test patient cancer
cover follow met
patient ajcc stage ii colon cancer patient stage
patient surgic resect
patient abl toler adjuv chemotherapi decis
regard need adjuv chemotherapi base presenc
molecular residu diseas
one test cover per primari cancer
test describ diagnost laboratori test patient
known cancer cover follow met
patient ajcc stage ii colorect cancer
patient presum cancer time test order
patient known cancer presum cancer
test indic
molecular residu diseas test may order time
month differ frequenc match nccn guidelin
surveil
anoth mrd test may also cover indic upon submiss
moldx technic assess test display accept analyt clinic
valid initi sequenc solid tumor tissu requir analyt
valid detect circul tumor dna requir analyt clinic
buy unchang target price august
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price august
diagnost tool
buy unchang target price august
diagnost tool
buy unchang target price august
diagnost tool
